Landmark BioVentures strengthens immunology and oncology non-clinical capabilities through strategic alliance with Axis Bio

Basel, Switzerland – December 12, 2024

Landmark BioVentures (LBV), an integrated and agile hub-and-spoke company pioneering drug development through lean and efficient approaches, today announced a strategic alliance with Axis Bio, a scientific and drug development-driven nonclinical contract research organization. This partnership marks a significant milestone in Landmark BioVentures' mission to deliver first-in-class therapeutics by enhancing its nonclinical pharmacology capabilities in immunology and oncology.

This alliance builds on the strong foundation of a longstanding relationship between LBV and Axis Bio, united by shared values of agility, innovation, and meaningful impact. Through this partnership, Axis Bio becomes a strategic extension of LBV's R&D Nexus, amplifying synergies and enabling dynamic cross-fertilization between the organizations. By combining their complementary expertise, the collaboration will streamline nonclinical drug development activities, particularly in pharmacology. The integrated model is designed to promote transparency, foster flexibility, and accelerate decision-making for more efficient and effective outcomes.

Zaki Sellam, co-founder and CEO of Landmark BioVentures, expressed enthusiasm stating, "This alliance reflects LBV's strategy to foster inclusivity and agility in its R&D activities. Axis Bio's scientific depth, combined with its ability to challenge and validate LBV nexus' in-house data, reinforces the robustness of the drug development process. Together, the companies are breaking traditional silos to ensure that innovative therapies reach patients more efficiently."

Dr. Jenny Worthington, co-founder and CEO at Axis Bio, shared her perspective, "This collaboration with LBV and its Nexus takes our partnership to a new level. We are proud to contribute to these promising programs, and the daily scientific exchange between our teams creates invaluable opportunities for mutual learning and innovation."

***

About Landmark BioVentures
Landmark BioVentures AG (LBV), founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company. LBV takes a unique model focused on lean operations, smart resource allocation and a diversified yet complementary pipeline of 10 first-in-class therapeutics, each being developed within a nexus of seven startups built from the ground up. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative deal-making in resource-constrained environments to streamline drug development by starting with the end in mind.

For more information, visit www.landmarkbioventures.com or follow us on LinkedIn.

About Axis Bio
Axis Bio is a preclinical contract research organization with specialist capabilities in oncology, inflammation and respiratory diseases. Services range from in vitro efficacy and mechanistic studies to in vivo target engagement, with each study tailored to the unique requirements of the client. Our clients are spread across the globe and include pharmaceutical and biotech businesses, university-based research organizations and virtual/semi-virtual development companies. We listen, guide and advise clients through every step of the preclinical efficacy testing process, to deliver clear and robust results in a timely and cost-effective manner. This approach applies whether we are simply carrying out the in-life phase of a study or providing a complete package of analysis including flow cytometry analysis, bioanalysis and blood analysis, along with a detailed interpretation of results and recommendations.

For more information, visit https://www.axisbio.co.uk/index or follow us on LinkedIn.